2.31

6.45% 0.14

After Hours: 2.31

Allogene Therapeutics Inc (ALLO)

Overview News Price History Option Chain Financials Discussions Forecast

Allogene Therapeutics Inc stock is traded at $2.31, with a volume of 7.34M. It is up +6.45% in the last 24 hours and down -11.15% over the past month. Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Previous Close:

$2.17

Open:

$2.24

24h Volume:

7.34M

Relative Volume:

0.80

Market Cap:

$797.01M

Revenue:

$22,000

Net Income/Loss:

$-190.89M

P/E Ratio:

-2.6607

EPS:

-0.8682

Net Cash Flow:

$-149.63M

1W Performance:

+9.48%

1M Performance:

-11.15%

6M Performance:

+120.00%

1Y Performance:

+80.47%

1-Day Range:

$2.22

$2.36

1-Week Range:

$2.08

$2.36

52-Week Range:

$0.8621

$4.46

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name

Allogene Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

(650) 457-2700

Address

210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO

Employee

152

Twitter

@AllogeneTx

Next Earnings Date

2026-05-12

Latest SEC Filings

ALLO's Discussions on Twitter

Compare ALLO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALLO Allogene Therapeutics Inc	2.31	748.70M	22,000	-190.89M	-149.63M	-0.8682
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-16-26	Upgrade	JP Morgan	Underweight → Neutral
Apr-10-26	Resumed	Jefferies	Buy
Jan-09-26	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Oct-10-25	Downgrade	JP Morgan	Neutral → Underweight
May-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Mar-14-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Aug-08-24	Resumed	Oppenheimer	Outperform
May-31-24	Initiated	Piper Sandler	Overweight
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy
Jun-03-22	Initiated	Robert W. Baird	Neutral
Feb-28-22	Reiterated	B. Riley Securities	Buy
Oct-20-21	Initiated	Cowen	Outperform
Oct-08-21	Downgrade	Goldman	Buy → Neutral
Oct-08-21	Downgrade	Stifel	Buy → Hold
Sep-23-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-21-21	Resumed	Jefferies	Buy
May-20-21	Upgrade	Truist	Hold → Buy
May-14-21	Initiated	B. Riley Securities	Buy
Jan-26-21	Upgrade	Stifel	Hold → Buy
Dec-10-20	Resumed	H.C. Wainwright	Buy
Nov-24-20	Initiated	BofA Securities	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Outperform
Jun-01-20	Downgrade	Raymond James	Outperform → Mkt Perform
May-29-20	Reiterated	H.C. Wainwright	Buy
May-19-20	Upgrade	ROTH Capital	Neutral → Buy
May-15-20	Upgrade	Guggenheim	Neutral → Buy
May-14-20	Reiterated	H.C. Wainwright	Buy
May-14-20	Downgrade	SunTrust	Buy → Hold
Apr-13-20	Initiated	SunTrust	Buy
Mar-13-20	Initiated	H.C. Wainwright	Buy
Mar-05-20	Initiated	Stifel	Hold
Feb-24-20	Initiated	Berenberg	Hold
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Nov-04-19	Initiated	Canaccord Genuity	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jun-05-19	Initiated	ROTH Capital	Neutral
May-31-19	Initiated	Guggenheim	Neutral
May-23-19	Initiated	Stifel	Hold
Mar-29-19	Initiated	Piper Jaffray	Overweight

View All

Allogene Therapeutics Inc Stock (ALLO) Latest News

08:32 AM

Allogene schedules May 13 webcast for Q1 results and business update - Stock Titan

08:32 AM

08:30 AM

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update - ChartMill

08:30 AM

May 05, 2026

Allogene Therapeutics ALPHA3 trial explores allogeneic CAR T potential in LBCL treatment - Traders Union

May 05, 2026

May 02, 2026

MSN Money - MSN

May 02, 2026

May 01, 2026

Allogene Therapeutics spotlights CTO participation in cell therapy innovation forum - Traders Union

May 01, 2026

JPMorgan, Allogene Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN

May 01, 2026

Allogene Therapeutics (ALLO) Closes $200.4M Public Offering of Common Stock - Insider Monkey

May 01, 2026

Apr 30, 2026

[ARS] Allogene Therapeutics, Inc. SEC Filing - Stock Titan

Apr 30, 2026

Allogene (NASDAQ: ALLO) proxy backs share authorization boost and pay votes - Stock Titan

Apr 30, 2026

Allogene Therapeutics (ALLO) price target increased by 16.66% to 8.83 - MSN

Apr 30, 2026

Apr 28, 2026

ALLO stock hits 2-year highs – analyst calls Allogene’s phase 2 trial data to treat lymphoma a ‘home run’ - MSN

Apr 28, 2026

Apr 27, 2026

Pfizer in deal with Allogene to develop cancer cell therapies - AOL.com

Apr 27, 2026

Allogene Therapeutics stock hits 52-week highhere's why - MSN

Apr 27, 2026

Allogene Therapeutics unveils ALLO-329 to target autoimmune disease with allogeneic CAR-T approach - Traders Union

Apr 27, 2026

Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN

Apr 27, 2026

Allogene jumps on analysis of Phase 2 data for B-cell lymphoma asset cema-cel - MSN

Apr 25, 2026

Allogene Therapeutics Expands Cancer Trial into South Korea and Australia - HarianBasis.co

Apr 25, 2026

Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In - Yahoo Finance

Apr 25, 2026

Apr 24, 2026

10 Best Growth Stocks Under $10 to Invest In - Insider Monkey

Apr 24, 2026

Allogene Therapeutics aims to redefine CAR T therapy with scalable allogeneic approach - Traders Union

Apr 24, 2026

Allogene Therapeutics announces public offering of $175M of common stock - MSN

Apr 24, 2026

Apr 23, 2026

Allogene Therapeutics (NASDAQ:ALLO) SVP Annie Yoshiyama Sells 9,586 Shares - MarketBeat

Apr 23, 2026

[SCHEDULE 13G] Allogene Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan

Apr 23, 2026

Allogene (NASDAQ: ALLO) SVP sale covers RSU taxes, holds 124,517 shares - Stock Titan

Apr 23, 2026

Allogene Therapeutics VP joins FiercePharmaEngage to drive M and A strategies in allogeneic cell therapy - Traders Union

Apr 23, 2026

Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Allogene Therapeutics (ALLO) - The Globe and Mail

Apr 23, 2026

H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO) - Insider Monkey

Apr 23, 2026

Apr 22, 2026

Allogene expands lymphoma trial to South Korea, Australia By Investing.com - Investing.com India

Apr 22, 2026